TIDMAMYT
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES
OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) NO. 596/2014 WHICH
FORMS PART OF DOMESTIC LAW IN THE UNITED KINGDOM PURSUANT TO THE
EUROPEAN UNION (WITHDRAWAL) ACT 2018 ("UK MAR"). UPON PUBLICATION
OF THIS ANNOUNCEMENT THIS INFORMATION IS NOW CONSIDERED IN THE
PUBLIC DOMAIN.
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN
PART, DIRECTLY OR INDIRECTLY IN, OR INTO OR FROM ANY JURISDICTION
IN WHICH THE SAME WOULD BE A VIOLATION OF THE LAWS OF SUCH
JURISDICTION. NEITHER THIS ANNOUNCEMENT, NOR ANYTHING CONTAINED
HEREIN, SHALL FORM THE BASIS OF, OR BE RELIED UPON IN CONNECTION
WITH, ANY OFFER OR COMMITMENT WHATSOEVER IN ANY JURISDICTION.
Amryt Pharma plc Announces the Cancellation of Admission of its
Ordinary Shares to Trading on AIM and Intention to Continue Listing
of ADSs on Nasdaq
DUBLIN, Ireland, and Boston MA, November 22, 2021, Amryt Pharma
plc (Nasdaq: AMYT, AIM: AMYT) ("Amryt" or the "Company"), a global,
commercial-stage biopharmaceutical company dedicated to acquiring,
developing and commercializing novel treatments for rare diseases,
today announces its intention to cancel the admission of its
ordinary shares of nominal value GBP0.06 each (the "Ordinary
Shares") to trading on AIM (the "AIM Delisting") with effect from
7:00 a.m. on 11 January 2022. The Company's last day of trading on
AIM will be 10 January 2022. Amryt will retain its listing on the
Nasdaq Global Select Market ("Nasdaq") of American Depositary
Shares, each representing five Ordinary Shares (the "ADSs"), under
its existing ticker symbol "AMYT". Existing holders of ADSs who do
not also hold Ordinary Shares do not need to take any action in
relation to the AIM Delisting. The Company will today post an
explanatory circular to shareholders (the "Circular") which
contains further information on the AIM Delisting and the process
to deposit Ordinary Shares for delivery of ADSs.
Summary
-- The AIM Delisting will take effect at 7:00 a.m. on 11 January
2022. Following the AIM Delisting, the Company's ADSs will remain listed
on Nasdaq and Ordinary Shares in the Company will only be publicly
tradeable in the form of Nasdaq-listed ADSs.
-- The board of directors of the Company (the "Board" and the "Directors")
believes that the AIM Delisting should further enhance the liquidity of
trading in the Company's securities by combining on Nasdaq the volume of
transactions from both the Nasdaq and AIM.
-- In the month to 17 November 2021, approximately 87 per cent. of trading
in the Ordinary Shares was in the form of ADSs on Nasdaq and as at 17
November 2021 73.2 per cent. of the Company's Ordinary Shares are
represented by ADSs tradeable on Nasdaq.
-- The Company is providing an opportunity for shareholders to deposit
their Ordinary Shares with the Company's ADS depositary in exchange for
delivery of ADSs, without cost, prior to the AIM Delisting becoming
effective on 11 January 2022.
Joe Wiley, CEO of Amryt Pharma, commented: "Increasing liquidity
in our shares and ensuring Amryt is an attractive investment
opportunity for existing and new investors is a core strategic
focus for Amryt. Since our Nasdaq listing in July 2020 and more
recently following the Chiasma acquisition, the vast majority of
trading in our shares has taken place on Nasdaq. We believe now is
the right time to reduce the complexity and significant resources
devoted to maintaining a dual listing. We believe concentrating
liquidity in one trading venue may attract increased investor
interest in our company and will benefit all shareholders."
Background
Amryt was originally incorporated in Ireland in 2015 as Amryt
Pharmaceuticals Designated Activity Company, with a focus on
acquiring, developing and commercialising innovative treatments to
help improve the lives of patients with rare and orphan diseases.
In April 2016, Amryt DAC was acquired by Fastnet Equity plc by way
of a reverse takeover under the AIM Rules for Companies published
by London Stock Exchange plc (the "London Stock Exchange") (the
"AIM Rules for Companies") and the Euronext Growth Rules. Upon the
acquisition of Amryt DAC, Fastnet Equity plc changed its name to
Amryt Pharma plc and the securities of the enlarged group were
readmitted to trading on AIM and Euronext Growth.
On 21 May 2019, Amryt Pharma plc announced that it had reached
an agreement to acquire Aegerion Pharmaceuticals, Inc. The
acquisition constituted a reverse takeover under the AIM Rules for
Companies and the Euronext Growth Rules. As part of the
acquisition, Amryt Pharma plc inserted a new company incorporated
in England and Wales, Amryt Pharma Holdings plc, as the new holding
company of the Amryt group by way of a court sanctioned scheme of
arrangement which became effective on 24 September 2019, on which
date Amryt Pharma Holdings plc changed its name to Amryt Pharma
plc. On the same date, the former Amryt Pharma plc re-registered as
a private company and changed its name to Amryt Pharma Holdings
Limited. On 25 September 2019, the Ordinary Shares of Amryt Pharma
plc were admitted to trading on AIM and Euronext Growth. On 8 July
2020, the Company completed a direct listing of ADSs representing
its Ordinary Shares on the Nasdaq Global Select Market, with each
ADS representing five Ordinary Shares. On 9 September 2020, the
Company cancelled the admission of its Ordinary Shares to trading
on the Euronext Growth Market.
On 5 May 2021, Amryt announced that it had reached an agreement
to acquire US-listed company, Chiasma, Inc., for consideration in
the form of ADSs. This acquisition completed on 5 August 2021 and
further increased the number of ADSs held in the United States and
traded on Nasdaq.
As at 17 November 2021, being the last practicable date prior to
the date of this announcement, approximately 73.2 per cent. of the
Company's Ordinary Shares are represented by ADSs tradeable on
Nasdaq. By reference to the volume of underlying Ordinary Shares,
approximately 87 per cent. of trading in the Company's Ordinary
Shares in the month to 17 November 2021 took place on Nasdaq (in
the form of ADSs). All shareholders who have not already deposited
their Ordinary Shares for delivery of ADSs are currently able to do
so at any time. Affiliates of the Company who deposit their
Ordinary Shares may be subject to limitations on resale of ADSs
under U.S. securities law.
The AIM Rules for Companies require that, unless the London
Stock Exchange otherwise agrees, the cancellation of a company's
shares from trading on AIM requires the consent of not less than 75
per cent. of votes cast by its shareholders given in a general
meeting. However, in the Company's case, given that the listing of
its ADSs on the Nasdaq Global Select Market (which is an AIM
Designated Market as defined in the AIM Rules for Companies)
enables shareholders to continue to trade their shares in the
Company in that format and, further, that there is a process
available to shareholders to deposit their Ordinary Shares for
delivery of ADSs prior to the AIM Delisting, the London Stock
Exchange has agreed that shareholder consent in a general meeting
is not required for the Company to proceed with the AIM
Delisting.
Reasons for the AIM Delisting
The Board has decided to implement the AIM Delisting for the
following reasons:
-- An increasingly smaller proportion of the trading in the Company's
Ordinary Shares is conducted on AIM compared to Nasdaq and a continuation
of the decline in this proportion would be likely to lead to a decrease
in the liquidity of the Ordinary Shares trading on AIM.
-- The AIM Delisting is expected to further enhance the liquidity of
trading in the Company's securities by combining on Nasdaq the volume of
transactions from both Nasdaq and AIM.
-- A Nasdaq-only listing structure provides for a streamlined operation
that showcases the global nature of the Company and places it more
clearly within the ranks of international biopharmaceutical companies
that are its true peers.
-- The cost of complying with the AIM Rules for Companies is duplicative of
that for complying with the Nasdaq market rules and the Company sees
advantages in reducing its cost base as it progresses its clinical
programmes and commercial strategy.
-- Internal financial and legal staff time spent on compliance with the AIM
Rules for Companies is duplicative of that required for compliance with
the Nasdaq market rules.
-- ADSs representing the Company's Ordinary Shares will still be tradeable
on Nasdaq.
Accordingly, the Directors believe that it is no longer in the
best interests of the Company or its shareholders as a whole for
the Company to retain admission of its Ordinary Shares to trading
on AIM.
In order to facilitate the transition to the sole listing on
Nasdaq, the Company is providing an opportunity for shareholders to
deposit their Ordinary Shares with the Company's ADS depositary in
exchange for delivery of ADSs, without cost, prior to the AIM
Delisting becoming effective on 11 January 2022. The ADSs will
continue to be traded on Nasdaq and the Company has no intention to
cancel the listing of its ADSs on the Nasdaq.
Effect of the AIM Delisting
Shareholders will no longer be able to buy and sell Ordinary
Shares on AIM after 10 January 2022. Holders of Ordinary Shares
should read "Information for holders of Ordinary Shares" below
which explains in more detail the process of depositing Ordinary
Shares for delivery of ADSs.
As a company incorporated in England and Wales, the Company will
continue to be subject to the requirements of the Companies Act
2006.
Following the AIM Delisting taking effect, the Company will no
longer be subject to the AIM Rules for Companies or be required to
retain the services of an independent nominated adviser. The
Company will also no longer be subject to the QCA Corporate
Governance Code or be required to comply with the continuing
obligations set out in the Disclosure Guidance and Transparency
Rules (the "DTRs") of the Financial Conduct Authority (the "FCA")
(insofar as they currently apply to the Company) or, provided the
Company's securities remain outside the scope of the regulation, UK
MAR. In addition, the Company and its shareholders will no longer
be subject to the provisions of the DTRs relating to the disclosure
of changes in significant shareholdings in the Company. The Company
will, however, continue to comply with all regulatory requirements
for the Nasdaq listing of ADSs, including all applicable rules and
regulations of the SEC.
Shareholders who continue to hold Ordinary Shares following the
AIM Delisting will continue to be notified in writing of the
availability of key documents on the Company's website, including
publication of annual reports and annual general meeting
documentation. Holders of ADSs will be able to continue to access
all such information via the Amryt website. Holders of Ordinary
Shares and ADSs will both be eligible to receive any future
dividends that may be declared.
Application of the City Code following the AIM Delisting
Following the AIM Delisting, as the Company will remain a public
limited company incorporated in England and Wales but its
securities will not be admitted to trading on a regulated market or
multilateral trading facility in the United Kingdom (or a stock
exchange in the Channel Islands or the Isle of Man), the City Code
on Takeovers and Mergers (the "City Code") will only apply to the
Company if it is considered by the Panel on Takeovers and Mergers
(the "Panel") to have its place of central management and control
in the United Kingdom (or the Channel Islands or the Isle of Man).
This is known as the "residency test". The way in which the test
for central management and control is applied for the purposes of
the City Code may be different from the way in which it is applied
by the United Kingdom tax authorities, Her Majesty's Revenue &
Customs ("HMRC"). Under the City Code, the Panel looks to where the
majority of the directors of the Company are resident, amongst
other factors, for the purposes of determining where the Company
has its place of central management and control.
None of the Directors is resident in the United Kingdom.
Accordingly, the Panel has confirmed to the Company that, following
the AIM Delisting, the City Code will not apply to the Company, and
the Company and its shareholders will therefore not have the
benefit of the protections the City Code affords, including, but
not limited to, the requirement that a person (together with
persons acting in concert with that person) who acquires an
interest in Ordinary Shares carrying 30 per cent. or more of the
voting rights in the Company or who increases an existing interest
of not less than 30 per cent. but not more than 50 per cent. of the
voting rights, must make a cash offer to all other shareholders at
the highest price paid by such person (or person acting in concert
with such person) in the 12 months before the offer was
announced.
Notwithstanding the above, the Company may become subject to the
City Code in the future if any changes to the Board composition
result in the majority of the Directors being resident in the
United Kingdom, Channel Islands or the Isle of Man.
Information for holders of Ordinary Shares
The Company's Ordinary Shares will continue to be traded on AIM
until market close (4.30 p.m. London time) on 10 January 2022.
Thereafter, holders of Ordinary Shares can still hold their
Ordinary Shares, but there will be no public market in the United
Kingdom on which the Ordinary Shares can be traded, and the
Ordinary Shares will not be tradeable on Nasdaq in this form.
To sell Ordinary Shares on a public market following the AIM
Delisting, shareholders would need to deposit their Ordinary Shares
for delivery of ADSs. Each ADS represents five Ordinary Shares. The
price of the Company's ADSs on Nasdaq are quoted in US dollars.
This deposit can be made at any time, including before the AIM
Delisting, subject in all cases to the provisions of, and the
limitations set forth in, the New York law governed deposit
agreement dated 24 September 2019, and amended and restated on 8
July 2020, between the Company, Citibank N.A., (the "Depositary")
and all holders and beneficial owners of ADSs issued thereunder
(the "Deposit Agreement"). A copy of the Deposit Agreement has been
filed with the SEC under cover of a Registration Statement on Form
F-6. You may obtain a copy of the Deposit Agreement from the SEC's
website (www.sec.gov). Please refer to Registration Number
333-233844 when retrieving such copy.
The Board considers that shareholders should consider depositing
their Ordinary Shares for delivery of ADSs prior to the AIM
Delisting on 11 January 2022 for the following reasons:
-- For those shareholders who hold their Ordinary Shares in certificated
form and wish to deposit their Ordinary Shares for delivery of ADSs, the
Company's Receiving Agent, Link Group, will facilitate, on the Company's
behalf, a block transfer process. Shareholders who hold their Ordinary
Shares in certificated form will find enclosed with the Circular a
personalised block transfer participation request form for use if they
wish to deposit their Ordinary Shares for delivery of ADSs. Subject to
the requisite documents being returned to Link Group by the required
deadline (being 1.00 p.m. on 9 December 2021), Link Group will arrange
for the relevant Ordinary Shares to be transferred to and through Link
Group's CREST account to the CREST account of the Custodian, which has
been appointed by the Depositary to safe keep the Ordinary Shares upon
deposit, so that the Depositary can arrange to deliver the corresponding
number of ADSs. The Custodian, on behalf of the Depositary, will hold all
deposited Ordinary Shares in a separate custody account for the benefit
of the holders and beneficial owners of ADSs.
-- Shareholders who elect to deposit their Ordinary Shares for delivery of
ADSs prior to the AIM Delisting will not incur a UK stamp duty, or SDRT,
charge. However, it is expected that shareholders who elect to deposit
their Ordinary Shares for delivery of ADSs following the AIM Delisting
will generally incur a stamp duty, or SDRT, charge, at a rate of 1.5 per
cent. of the market value of the Ordinary Shares being deposited, to the
UK taxation authority, HMRC.
-- Ordinarily, shareholders who deposit their Ordinary Shares for delivery
of ADSs are charged an ADS issuance fee, by the Depositary, of up to
US$0.05 per ADS. However, no ADS issuance fees will be charged to
shareholders who elect to deposit their Ordinary Shares for delivery of
ADSs from the date of this announcement until (and including) 10 January
2022, being the anticipated last day of trading of the Company's Ordinary
Shares on AIM. Thereafter, ADS issuance fees of up to US$0.05 per ADS may
be charged by the Depositary in connection with any future conversions of
Ordinary Shares into ADSs.
-- Ordinary Shares may be deposited for delivery of ADSs only in multiples
of five Ordinary Shares. It is not possible to receive a fraction of an
ADS, so in the event that the deposit is completed after the AIM
Delisting, there is a risk that shareholders will be left with a small
number of Ordinary Shares (up to a maximum of four shares) which cannot
be deposited for delivery of ADSs. If the deposit is made before the AIM
Delisting has taken effect, any residual Ordinary Shares can be sold by
shareholders on AIM prior to, and including, 10 January 2022 so long as
those Ordinary Shares are in uncertificated form. Shareholders who hold
their Ordinary Shares in certificated form may elect to donate their
residual shares to the charity Share Gift by making that election on
their personalised block transfer participation request form.
Shareholders who do not elect to participate in the block
transfer process can utilise the services of a broker who is able
to facilitate deposits of Ordinary Shares at the shareholder's
convenience.
Shareholders whose Ordinary Shares are held in uncertificated
form in CREST and who wish to deposit their Ordinary Shares for
delivery of ADSs, should contact their broker without delay to
request that their Ordinary Shares are deposited.
Amryt advises holders of Ordinary Shares to seek independent
financial advice regarding the AIM Delisting and the deposit of
their Ordinary Shares for delivery ADSs.
Information on the process to deposit Ordinary Shares for
delivery of ADSs and the forms to be completed accompany the
Circular. The information and forms, and contacts at the Company's
Receiving Agent, Link Group, in respect of completion of the block
transfer participation request form for certificated holders, and
the Company's ADS depositary, Citibank, are included on Amryt's
website.
UK tax treatment
Amryt is not able to provide shareholders with any form of
taxation advice and shareholders are strongly advised to seek their
own professional advice in order to ascertain the consequences for
them of continuing to hold Ordinary Shares following the AIM
Delisting becoming effective or depositing Ordinary Shares for
delivery of ADSs.
The following summary does not constitute legal or tax advice
and is not exhaustive. The Company's understanding of the current
position for individuals who are UK resident and UK domiciled for
relevant tax purposes is as follows but it should be noted that the
position on certain points is not free from uncertainty and that
the Company has not taken steps to confirm the current position
with HMRC. Therefore, the following should not be relied upon by
shareholders (and the Company accepts no liability in respect of
any such reliance on any information provided herein on taxation
matters):
-- Some investors purchase AIM-quoted shares because they may be classed as
unlisted/unquoted securities which may qualify for relief from
inheritance taxation and certain other preferential tax benefits. The AIM
Delisting should not, in itself, prevent the Ordinary Shares (and,
therefore, continued holdings of such Ordinary Shares) from qualifying as
unlisted/unquoted securities for the purposes of certain specific UK tax
rules (notably, the UK inheritance tax business property relief rules).
-- Under HMRC's stated practice those shareholders who elect to deposit
their holdings of Ordinary Shares for delivery of Nasdaq-listed ADSs
should not be considered as disposing of the Ordinary Shares for UK
capital gains tax purposes when transferring the shares to the Company's
ADS depositary, Citibank, in exchange for issue of ADSs on the basis that
the shareholder retains beneficial ownership of the Ordinary Shares.
Shareholders should be aware that HMRC to date has not published detailed
guidance on the treatment of ADSs for inheritance tax purposes.
Shareholders who elect to deposit their holdings of Ordinary
Shares for delivery of Nasdaq-listed ADSs prior to the AIM
Delisting should not incur a stamp duty, or SDRT, charge. It is
expected that shareholders who elect to deposit their holdings of
Ordinary Shares for delivery of Nasdaq-listed ADSs following the
AIM Delisting will generally incur a stamp duty, or SDRT, charge at
the rate of 1.5 per cent. of the market value of the Ordinary
Shares being deposited.
It is strongly recommended that shareholders obtain appropriate
professional advice in respect of these and other taxes.
Expected timetable for the AIM Delisting
Date of announcement and dispatch of 22 November 2021
the Circular and enclosed documents
Last date for receipt by Link Group from 9 December 2021 at 1.00
certificated shareholders of duly completed p.m.
block transfer participation request
forms and original share certificates
Expected date of issuance of ADSs to 7 January 2022
block transfer participants
Expected date of posting of ADS confirmations 7 January 2022
to shareholders by Citibank
Last date for receipt by Citibank from 10 January 2022 at 3:00
CREST holders of duly completed issuance p.m.
forms
Last day of dealings in the Ordinary 10 January 2022
Shares on AIM
Cancellation of admission to trading 11 January 2022 at 7.00
on AIM of the Ordinary Shares a.m.
-----------------------
Notes
1. References to time in this announcement are to London time unless
otherwise stated.
2. Each of the times and dates in the above timetable are subject to
change. If any of the above times and/or dates change, the revised times
and/or dates will be notified to shareholders by announcement through a
Regulatory Information Service.
The person responsible for arranging the release of this
announcement on behalf of the Company was Rory Nealon, CFO/COO and
Company Secretary.
About Amryt
Amryt is a global commercial-stage biopharmaceutical company
focused on acquiring, developing and commercializing innovative
treatments to help improve the lives of patients with rare and
orphan diseases. Amryt comprises a strong and growing portfolio of
commercial and development assets.
Amryt's commercial business comprises three orphan disease
products -- metreleptin (Myalept(R)/ Myalepta(R)); oral octreotide
(Mycapssa(R)); and lomitapide (Juxtapid(R)/ Lojuxta(R)).
Myalept(R)/Myalepta(R) (metreleptin) is approved in the US
(under the trade name Myalept(R)) as an adjunct to diet as
replacement therapy to treat the complications of leptin deficiency
in patients with congenital or acquired generalized lipodystrophy
(GL) and in the EU (under the trade name Myalepta(R)) as an adjunct
to diet for the treatment of leptin deficiency in patients with
congenital or acquired GL in adults and children two years of age
and above and familial or acquired partial lipodystrophy (PL) in
adults and children 12 years of age and above for whom standard
treatments have failed to achieve adequate metabolic control. For
additional information, please follow this
https://www.globenewswire.com/Tracker?data=e6FPse95NnkNAIgFRwGEqLMteLP363HD1UUzYm8h8oO47fQwnChLLqNzuNAC9Ba3U5-DDaoqwuAZqbnyPrFfVlxymQp9tsfnddkbc9fxYdtVmFdy1xthPJ1TNQ5X2NuzcPXxhXXEj1xTnsC-jzHkdJXPT03YPKcT8nr3GlI3viA=
link.
Mycapssa(R) (oral octreotide) is approved in the US for
long-term maintenance therapy in acromegaly patients who have
responded to and tolerated treatment with octreotide or lanreotide.
Mycapssa(R) is the first and only oral somatostatin analogapproved
by the FDA. Mycapssa(R) has also been submitted to the EMA for
regulatory approval. For additional information, please follow this
https://www.globenewswire.com/Tracker?data=e6FPse95NnkNAIgFRwGEqFYehsA-jih3MyrjXZasW3rKaxratv-N6Vd9t51ca8s4JgsFidVJ5HkgdqokiAnjaQ==
link.
Juxtapid(R)/Lojuxta(R) (lomitapide) is approved as an adjunct to
a low-fat diet and other lipid-lowering medicinal products for
adults with the rare cholesterol disorder, Homozygous Familial
Hypercholesterolaemia ("HoFH") in the US, Canada, Colombia,
Argentina and Japan (under the trade name Juxtapid(R)) and in the
EU, Israel and Brazil (under the trade name Lojuxta(R)). For
additional information, please follow this
https://www.globenewswire.com/Tracker?data=e6FPse95NnkNAIgFRwGEqOYgqkmxJzVEH1Jyy1W12z5gDlamypRFy_KYDh08SbePleHKy_ZmGAh4uZjiMSXrIQ==
link.
Amryt's lead development candidate, Oleogel-S10 (Filsuvez(R)) is
a potential treatment for the cutaneous manifestations of
Junctional and Dystrophic Epidermolysis Bullosa ("EB"), a rare and
distressing genetic skin disorder affecting young children and
adults for which there is currently no approved treatment.
Filsuvez(R) has been selected as the brand name for Oleogel-S10.
The product does not currently have regulatory approval to treat EB
but has been submitted to the FDA for approval and in June 2021,
Amryt received confirmation from the FDA that its NDA for
Oleogel-S10 had been accepted and granted priority review. The FDA
also set a target PDUFA date of November 30, 2021. In Europe, a MAA
for Oleogel-S10 was accepted for assessment by the EMA in March
2021.
Amryt's pre-clinical gene therapy candidate, AP103, offers a
potential treatment for patients with Dystrophic EB, and the
polymer-based delivery platform has the potential to be developed
for the treatment of other genetic disorders.
Amryt also intends to develop oral medications that are
currently only available as injectable therapies through its
Transient Permeability Enhancer (TPE(R) ) technology platform. For
more information on Amryt, including products, please visit
https://www.globenewswire.com/Tracker?data=ZvZyk5vEgv9DxgDNHQS6L_WV8-S0Q4maaajmbeQBuSCh1CzjKMTqfb7ixr7X-LwSGRo7t_iHdU6vqr-XxUG8he8GLnptTKshxk-YCl8mrfs=
www.amrytpharma.com.
Financial Advisors
Shore Capital (Daniel Bush, Mark Percy, John More) are NOMAD and
Joint Broker to Amryt in the UK. Stifel (Ben Maddison) are Joint
Broker to the company in the UK.
Forward-Looking Statements
This announcement may contain forward-looking statements and the
words "expect", "anticipate", "intends", "plan", "estimate", "aim",
"forecast", "project" and similar expressions (or their negative)
identify certain of these forward-looking statements. The
forward-looking statements in this announcement are based on
numerous assumptions and Amryt's present and future business
strategies and the environment in which Amryt expects to operate in
the future. Forward-looking statements involve inherent known and
unknown risks, uncertainties and contingencies because they relate
to events and depend on circumstances that may or may not occur in
the future and may cause the actual results, performance or
achievements to be materially different from those expressed or
implied by such forward-looking statements. These statements are
not guarantees of future performance or the ability to identify and
consummate investments. Many of these risks and uncertainties
relate to factors that are beyond Amryt's ability to control or
estimate precisely, such as future market conditions, the course of
the COVID-19 pandemic, currency fluctuations, the behaviour of
other market participants, the outcome of clinical trials, the
actions of regulators and other factors such as Amryt's ability to
obtain financing, changes in the political, social and regulatory
framework in which Amryt operates or in economic, technological or
consumer trends or conditions. Past performance should not be taken
as an indication or guarantee of future results, and no
representation or warranty, express or implied, is made regarding
future performance. No person is under any obligation to update or
keep current the information contained in this announcement or to
provide the recipient of it with access to any additional relevant
information that may arise in connection with it. Such
forward-looking statements reflect the Company's current beliefs
and assumptions and are based on information currently available to
management.
Contacts
Joe Wiley, CEO / Rory Nealon, CFO/COO, +353 (1) 518 0200,
https://www.globenewswire.com/Tracker?data=UE1-vvJjYr5NvImMiIglqGIXwLfBRU8u3JrjqnWA1twUqnah1bqwJtyYkIhFozLQCicYuNi4fmOq83VbgA3z3qOrDB__gvdH2GpLwGdS5FA=
ir@amrytpharma.com
Daniel Bush, Shore Capital, NOMAD +44 (0) 207 408 4090,
amrytcorporate@shorecap.co.uk
Tim McCarthy, LifeSci Advisors, LLC, +1 (212) 915 2564,
tim@lifesciadvisors.com
Amber Fennell, Consilium Strategic Communications, +44 (0) 203
709 5700,
https://www.globenewswire.com/Tracker?data=a4ciBArHdJE04oX7_hH8rhfVyRuAPfhl-NedoLr5pPV6U10DMH3GehfE8R4TIfOmYlMYHYeqQuGAWNS2_-cwPyp-L0idLVnJEuiC-aD_6YSY29aH18DkEsVvMoCXC-qa
fennell@consilium-comms.com
(END) Dow Jones Newswires
November 22, 2021 02:00 ET (07:00 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Amryt Pharma (LSE:AMYT)
Gráfica de Acción Histórica
De Dic 2024 a Ene 2025
Amryt Pharma (LSE:AMYT)
Gráfica de Acción Histórica
De Ene 2024 a Ene 2025
